Last reviewed · How we verify

Intravenous Ascorbate — Competitive Intelligence Brief

Intravenous Ascorbate (Intravenous Ascorbate) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antioxidant/Pro-oxidant agent. Area: Oncology.

phase 3 Antioxidant/Pro-oxidant agent Reactive oxygen species generation; multiple indirect targets Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Intravenous Ascorbate (Intravenous Ascorbate) — University of Malaya. Intravenous ascorbate (vitamin C) acts as a pro-oxidant at high concentrations to generate reactive oxygen species that selectively kill cancer cells while supporting immune function.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Intravenous Ascorbate TARGET Intravenous Ascorbate University of Malaya phase 3 Antioxidant/Pro-oxidant agent Reactive oxygen species generation; multiple indirect targets

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antioxidant/Pro-oxidant agent class)

  1. University of Malaya · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intravenous Ascorbate — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-ascorbate. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: